123 related articles for article (PubMed ID: 22398230)
21. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
[TBL] [Abstract][Full Text] [Related]
22. Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
Sin C; Mahé E; Sigal ML
Diabetes Metab; 2012 Dec; 38(6):571-3. PubMed ID: 23183246
[TBL] [Abstract][Full Text] [Related]
23. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
24. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
[No Abstract] [Full Text] [Related]
25. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
27. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
28. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.
Saito T; Ohnuma K; Suzuki H; Dang NH; Hatano R; Ninomiya H; Morimoto C
Diabetes Res Clin Pract; 2013 Oct; 102(1):e8-e12. PubMed ID: 23937822
[TBL] [Abstract][Full Text] [Related]
29. A case of drug-induced hepatic injury associated with sitagliptin.
Toyoda-Akui M; Yokomori H; Kaneko F; Shimizu Y; Takeuchi H; Tahara K; Motoori T; Ohbu M; Oda M; Hibi T
Intern Med; 2011; 50(9):1015-20. PubMed ID: 21532224
[TBL] [Abstract][Full Text] [Related]
30. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
31. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
32. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
33. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
[TBL] [Abstract][Full Text] [Related]
34. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
36. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Miller S; St Onge EL
Ann Pharmacother; 2006; 40(7-8):1336-43. PubMed ID: 16868220
[TBL] [Abstract][Full Text] [Related]
37. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
[TBL] [Abstract][Full Text] [Related]
38. Sitagliptin.
Drucker D; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Feb; 6(2):109-10. PubMed ID: 17342863
[No Abstract] [Full Text] [Related]
39. [Sitagliptine (Januvia)].
Duh D; Vandevijver A
J Pharm Belg; 2008 Mar; 63(1):31-2. PubMed ID: 18479082
[No Abstract] [Full Text] [Related]
40. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
Yokota K; Igaki N
Intern Med; 2012; 51(15):2041-4. PubMed ID: 22864134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
